GlycoEra AG (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- May 27, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $130,000,000
Company Info
- Traction
- The lead program, GE8820, has demonstrated deep and sustained IgG4 depletion in various models, giving it broad potential across numerous disease settings.
- Organizations Involved
- Novo Holdings, Catalio Capital Management, LifeArc Ventures, QIA, Sofinnova Partners, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital
- Company Description
- GlycoEra AG is a biotechnology company dedicated to developing best-in-class protein degraders to transform the treatment of autoimmune diseases. Harnessing the power of glycoengineering to precisely target and degrade circulating, disease-causing proteins, GlycoEra is advancing a differentiated platform and pipeline of therapies targeting autoimmune diseases.
- Market
- Autoimmune Diseases
- Location
- Wädenswil, Switzerland
- Coinvestors
- Novo Holdings, Catalio Capital Management, LifeArc Ventures, QIA, Sofinnova Partners, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital